Arrowhead Pharmaceuticals
A Platform, Not a Product Story
Most biotechnology research is organised around products. Arrowhead is better understood as a delivery platform moving through three stages of validation: scientific validation, commercial validation and, ultimately, economic validation at scale.
The central investment question is not whether RNA interference works — Alnylam and the wider field have answered that. The question is whether Arrowhead’s TRiM platform can repeatedly deliver durable gene silencing across liver, lung, adipose tissue and the central nervous system, and whether management can convert that breadth into attractive returns without losing focus.
This is a living investment dossier. It separates what is proven from what is promising, gives the obesity franchise option value rather than certainty, and identifies the clinical and commercial events that would strengthen or invalidate the thesis.
REDEMPLO proves Arrowhead can take a wholly owned RNAi drug from platform to market. SHTG and broader hypertriglyceridaemia determine whether it becomes a franchise. Extrahepatic delivery and obesity determine whether Arrowhead deserves to be valued as a multi-tissue platform company.
This publication is for informational purposes only and does not constitute investment advice. Biotechnology investing involves clinical, regulatory, commercial, financing and competitive risk.
Six Things That Matter Right Now
FDA approval of REDEMPLO in November 2025 moved Arrowhead from a perpetual development story into a commercial-stage company. Subsequent approvals in China, Australia and the European Union broaden the proof of execution.
FCS is commercially useful but too small to explain the equity value. The decisive question is whether Phase 3 data support expansion into severe and broader hypertriglyceridaemia.
Arrowhead’s reusable delivery architecture now reaches hepatocytes, lung, adipose tissue and the CNS. Each tissue validated expands the set of genes the company can address.
ARO-INHBE and ARO-ALK7 are differentiated because they may complement incretins through body-composition and metabolic effects. Early data are encouraging, but the programmes remain too immature for deterministic valuation.
Amgen, GSK, Takeda and Sarepta validate target selection and reduce the capital burden. They also transfer some economics and create dependence on partner execution.
The pipeline looks diversified, but near-term valuation remains concentrated in plozasiran, launch execution and a compressed calendar of late-stage readouts.
Arrowhead should not yet be valued like a mature Alnylam. But it should no longer be analysed like a conventional clinical-stage biotech. It sits in the unstable — and potentially rewarding — middle ground between the two.
Arrowhead at the Inflection Point
Is Arrowhead becoming a durable RNAi franchise — or is the valuation running ahead of the evidence?
Arrowhead Pharmaceuticals, Inc. is a Pasadena, California-headquartered biopharmaceutical company that designs and develops RNA interference (RNAi) therapeutics — a class of medicines that silence disease-causing genes at the messenger RNA level, before the harmful protein is ever made. Where traditional small-molecule drugs and antibodies act on proteins after they are produced, RNAi drugs intervene upstream, allowing for durable, infrequent dosing and, in principle, applicability to a wide range of targets historically considered “undruggable.”
The company’s core technology is its proprietary TRiM™ (Targeted RNAi Molecule) platform, which conjugates small interfering RNA molecules to a targeting ligand — most commonly GalNAc, which binds a receptor expressed almost exclusively on hepatocytes. Arrowhead has more recently extended TRiM-based delivery to the lung, adipose tissue, and the central nervous system, broadening its addressable biology well beyond the liver-only scope that defined the RNAi field a decade ago.
The business model is a hybrid: Arrowhead wholly owns and commercializes its most advanced cardiometabolic assets itself, while out-licensing selected earlier-stage programs to Takeda, GSK, Amgen and Sarepta Therapeutics for upfront payments, milestones and royalties — giving the company both near-term, partner-funded cash flow and long-term, high-margin optionality on the assets it keeps.
The flagship achievement is plozasiran, marketed as REDEMPLO™, an RNAi therapeutic that reduces hepatic ApoC3 production. REDEMPLO received FDA approval in November 2025 for familial chylomicronemia syndrome (FCS), becoming Arrowhead’s first FDA-approved, self-commercialized product after more than three decades as a research-stage company. Management has been explicit: FCS is the beachhead, not the ceiling, with severe and broader hypertriglyceridemia data expected in the second half of 2026.
Beyond plozasiran, Arrowhead runs one of the deepest clinical-stage RNAi pipelines in the industry — roughly 17–18 distinct programs spanning Cardiometabolic, Liver, Pulmonary and CNS franchises, an unusual breadth for a company of Arrowhead’s size that reflects the chemistry-driven, reusable nature of its R&D engine.
Arrowhead is crossing the line from platform promise to commercial proof.
From Delivery Failure to the TRiM Platform
What does Arrowhead’s history tell us about management’s ability to navigate scientific setbacks?
Arrowhead’s roots trace to 1989, when it was founded as Arrowhead Research Corporation, a diversified holding company incubating early-stage technologies across electronics, energy and life sciences — entirely disconnected from the RNAi-focused biopharmaceutical company it is today. The strategic pivot began under Christopher Anzalone’s leadership, which started in December 2007, progressively narrowing the company’s focus toward RNA interference.
The single most important inflection point came in 2011, when Arrowhead acquired Roche’s discarded RNAi assets, technology and IP — including what became its Madison, Wisconsin site — after Roche, Merck and others wound down internal RNAi programs amid industry-wide delivery setbacks. The acquisition gave Arrowhead a chemistry and IP foundation far stronger than its size would otherwise have supported.
In 2016, Arrowhead discontinued its second-generation “EX1” delivery vehicle after a hepatotoxicity signal emerged in clinical testing — a setback that could have been existential. Instead, management used it to accelerate the transition to the TRiM™ platform and formally renamed the company Arrowhead Pharmaceuticals, Inc., completing its transformation into a focused clinical-stage biopharmaceutical company.
The subsequent decade has been characterized by rapid, compounding pipeline expansion: once TRiM-based GalNAc conjugation was validated in the liver, Arrowhead systematically applied it against a widening set of genetically validated targets, while separately extending delivery into lung, adipose tissue and the CNS. The most consequential recent milestone came on November 18, 2025, when the FDA approved REDEMPLO for FCS — the culmination of nearly two decades under Anzalone’s leadership. Early uptake was rapid: prescriptions grew nearly threefold quarter over quarter, and more than 40% in a single four-week window in early 2026.
The company’s defining asset has been its willingness to survive failed delivery technologies and rebuild around better chemistry.
Leadership, Capital Allocation and Execution
Can the team that built the platform also build a globally integrated commercial company?
CEO since December 2007 — nearly two decades of strategic continuity, one of the longest tenures in clinical-stage biopharma. Led the 2011 Roche RNAi asset acquisition and the 2016 TRiM pivot, both existential-risk decisions that proved foundational. Under his leadership, Arrowhead has executed licensing agreements with Amgen, GSK, Takeda and Sarepta generating well over $1 billion in upfront and milestone payments.
Joined April 2025, succeeding 16-year CFO Kenneth Myszkowski in a deliberate, low-risk transition. Brings 25+ years of financial leadership including Global Head of FP&A at Walgreens Boots Alliance (2019–2024) and CFO of Bayer U.S. (2016–2019) — direct experience with pharmaceutical commercial launch economics now central to Arrowhead’s first year as a revenue-generating company.
Architect of the clinical strategy that took plozasiran from first-in-human through approval and into three simultaneous Phase 3 label-expansion trials. Designed the tirzepatide combination strategy for ARO-INHBE and ARO-ALK7 and has presented Arrowhead’s data at ACC and EASL, including the SHASTA-2 results published in JAMA Cardiology.
Holds a dual operational and legal mandate — overseeing the REDEMPLO commercial launch, manufacturing coordination across a dozen concurrent trials, and the IP estate protecting TRiM chemistry patents against Ionis, Alnylam and other RNAi and antisense competitors in an increasingly litigious field.
The board of directors includes Christopher Anzalone (Chairman), Mauro Ferrari, Hongbo Lu, Adeoye Olukotun, Michael S. Perry, Victoria Vakiener, William Waddill and Matthew Cohen, combining deep pharmaceutical R&D and regulatory expertise with capital markets governance experience. Insider transaction patterns — including CMO James Hamilton retaining the substantial majority of his holdings after a modest January 2026 sale — do not suggest unusual distress selling.
Long-tenured scientific leadership has created unusual strategic continuity; the next test is commercial scale.
The Portfolio: From REDEMPLO to Multi-Tissue RNAi
Which programmes can convert TRiM from a technology platform into a diversified earnings platform?
Arrowhead’s portfolio is best understood as a single reusable delivery-and-chemistry platform deployed against a widening set of genetically validated disease targets, organized into four franchises: Cardiometabolic, Liver, Pulmonary and Central Nervous System. As of mid-2026, the company discloses roughly 17–18 distinct drug candidate/indication combinations.
Plozasiran (REDEMPLO™) reduces hepatic ApoC3, allowing more efficient triglyceride clearance. Approved in FCS on the strength of the pivotal PALISADE trial, its development was never designed to stop there: SHASTA-3 and SHASTA-4 are evaluating severe hypertriglyceridemia (SHTG, millions of US patients), and MUIR-3 — the largest trial in the program at over 1,300 participants — is evaluating the still-broader hypertriglyceridemia population. All three have estimated primary completion around October 2026. The preceding Phase 2b SHASTA-2 trial showed placebo-adjusted triglyceride reductions of 57% at 24 weeks, with over 90% of patients reaching triglycerides below 500 mg/dL.
Zodasiran (ARO-ANG3) silences hepatic ANGPTL3 and is in Phase 3 (YOSEMITE trial) for homozygous familial hypercholesterolemia (HoFH). Its key differentiation versus Regeneron/Ultragenyx’s approved Evkeeza is dosing convenience — quarterly subcutaneous versus biweekly — with peak sales estimates in the $500–800 million range.
Olpasiran, licensed to Amgen since 2016, reduces apolipoprotein(a) and is in Phase 3 including the 11,000-participant OCEAN(a)-PreEvent outcomes trial. ARO-INHBE and ARO-ALK7 — the emerging obesity/metabolic franchise — are covered in depth in Chapter 9. Additional programs include GSK4532990 (MASH, Phase 2b), ARO-DIMER-PA (a first-of-its-kind dual PCSK9/APOC3 silencer, Phase 1), and ARO-PNPLA3 (MASH, Phase 1).
In the Liver franchise, fazirsiran (partnered with Takeda) is in Phase 3 for AATD-associated liver disease, and ARO-HBV (licensed to GSK) is in Phase 2 for chronic hepatitis B. Pulmonary and CNS round out the platform: ARO-RAGE (Phase 2, inflammatory lung disease), ARO-MMP7 (Phase 1, pulmonary fibrosis, Sarepta), ARO-MAPT (Phase 1, Alzheimer’s), ARO-ATXN2 (Phase 1, spinocerebellar ataxia 2, Sarepta) and SRP-1005 (Huntington’s, Sarepta) — the company’s most recent frontier of tissue expansion.
REDEMPLO is the beachhead, but the value lies in indication expansion and a repeatable pipeline engine.
Commercial Validation and the Scaling Challenge
Can a newly built commercial organisation scale without destroying the economics that make RNAi attractive?
Arrowhead’s go-to-market model differs depending on whether an asset is wholly owned (currently, only REDEMPLO) or partnered (the majority of the pipeline by program count). For REDEMPLO, the prescriber base is highly concentrated among lipidologists, preventive cardiologists and endocrinologists — a commercial advantage for a first-ever product launch, since it requires a smaller, scientifically sophisticated commercial team rather than a large primary-care sales force. Early prescription growth (nearly tripling quarter over quarter) suggests strong execution.
At a $60,000 annual WAC, REDEMPLO fits the classic ultra-orphan reimbursement profile: high per-patient cost justified by small budget impact and strong clinical rationale. As plozasiran’s addressable population expands into SHTG and broader HTG, the payer dynamic becomes substantially more complex — a drug priced at ultra-orphan levels cannot realistically be sustained at the same price point across a population of potentially millions, making step-therapy, prior authorization and price concessions a near-certainty. Management’s framing of REDEMPLO “as a platform, not a one-off drug” suggests the company is already planning tiered, indication-specific pricing.
For the majority of the pipeline — programs partnered with Amgen, GSK, Takeda and Sarepta — Arrowhead’s effective customer is the pharmaceutical partner itself. This partnered model has generated over $1 billion in cumulative upfront and milestone payments since 2016, effectively subsidizing the R&D costs of the earlier-stage internal pipeline without requiring the company to build commercial infrastructure for every program simultaneously. The most significant go-to-market evolution ahead is REDEMPLO’s eventual label expansion into SHTG, which would require Arrowhead to build a substantially larger commercial organization capable of engaging general cardiologists and primary care physicians — its first true test as a mainstream commercial biopharmaceutical company.
Arrowhead must evolve from selling an ultra-orphan medicine to competing in population-scale cardiometabolic markets.
The Second Generation of RNA Interference
Where does TRiM genuinely differentiate Arrowhead within the second generation of RNA medicines?
For roughly the first fifteen years following its 1998 discovery, RNAi was a technology with compelling biology but an unsolved delivery problem — the same wave of industry retrenchment that let Arrowhead acquire Roche’s RNAi assets cheaply in 2011. The modality’s fortunes reversed decisively with the maturation of GalNAc-conjugate chemistry, independently commercialized at blockbuster scale by Alnylam and by Arrowhead through its own proprietary TRiM chemistry. The industry’s current frontier — in which Arrowhead is a leading participant — is extending this proven liver-delivery chemistry to the lung, adipose tissue and the central nervous system, each presenting delivery challenges analogous to the one the industry spent the 2000s and 2010s solving.
The lipid-lowering drug market has historically been dominated by statins and PCSK9 inhibitor antibodies that leave a substantial “residual risk” population with elevated triglycerides inadequately served — the core opportunity ApoC3- and ANGPTL3-targeted therapies are designed to address, reinvigorated by a decade of genetic-validation-driven target discovery (APOC3, ANGPTL3, HSD17B13, PNPLA3, INHBE, ACVR1C/ALK7).
The obesity and metabolic disease market is in the midst of the most significant re-rating of the past decade: the global GLP-1 market is projected to grow from roughly $82 billion in 2026 to $185 billion by 2033, with Americans on GLP-1 therapy projected to roughly 2.5x to approximately 25 million by 2030. Rather than compete head-on with incretin therapies, Arrowhead has explicitly designed ARO-INHBE and ARO-ALK7 as adjunctive combination therapies that amplify and improve the quality of GLP-1-driven weight loss — a picks-and-shovels-style complement to, rather than a direct competitor of, the GLP-1 incumbents.
RNAi has already been clinically validated; the competitive frontier is now delivery beyond the liver.
The Competitive Battlefield
Does dosing convenience and target breadth translate into durable competitive advantage?
Ionis Pharmaceuticals is Arrowhead’s most direct and immediate threat: its GalNAc-conjugated ASO olezarsen (Tryngolza) also targets ApoC3, and critically, Ionis currently holds first-mover advantage in the larger indication — Tryngolza is approved in both FCS and, as of June 2026, severe hypertriglyceridemia, while REDEMPLO remains approved only in FCS with SHASTA-3/4 data still pending. Analysts nonetheless forecast blockbuster status for both drugs, suggesting the market is pricing this as a genuine multi-player category.
Regeneron/Ultragenyx’s Evkeeza is the incumbent zodasiran must displace in HoFH; zodasiran’s quarterly dosing versus Evkeeza’s biweekly administration is a meaningful but not decisive advantage. Alnylam Pharmaceuticals is not a direct competitor in any disclosed program but is the RNAi platform bellwether investors benchmark Arrowhead against, and maintains a broader, more mature CNS pipeline. Novo Nordisk and Eli Lilly are simultaneously the incumbents shaping the addressable obesity market Arrowhead’s programs depend on, and potential future partners.
Beyond Evkeeza, the ANGPTL3 space is becoming crowded with next-generation modalities — Verve Therapeutics’ gene-editing VERVE-201 (with Eli Lilly), Lilly’s own ASO solbinsiran, and a separate Regeneron/Alnylam siRNA collaboration — meaning zodasiran will compete against gene editing, ASO and a rival siRNA simultaneously. Arrowhead’s principal competitive advantages remain: pipeline breadth relative to market cap, demonstrated extrahepatic delivery, a capital-efficient partnering track record, and first-mover positioning in RNAi-plus-GLP-1 combination obesity therapy.
Arrowhead competes simultaneously against RNAi peers, antisense drugs, antibodies, gene editing and entrenched commercial incumbents.
The Expanding Cardiometabolic Opportunity
Which market opportunities are investable today, and which should remain option value?
FCS is an ultra-rare disease with diagnosed US prevalence in the low single-digit thousands — even full penetration at a $60,000 WAC represents a revenue opportunity in the hundreds of millions of dollars at most, not the basis for a multi-billion dollar equity valuation. This is precisely why SHASTA-3/4 and MUIR-3 are the central near-term catalyst: they determine whether plozasiran’s addressable market expands by one to three orders of magnitude.
Severe hypertriglyceridemia affects an estimated 1–2% of US adults (~2.7 million diagnosed patients), with the SHTG market across seven major markets estimated at approximately $1.4 billion in 2023 and growing — notably, close to half of diagnosed SHTG patients currently receive no treatment at all. The broader hypertriglyceridemia population MUIR-3 targets is larger still, affecting roughly a third of US adults (over 85 million people), though the clinically actionable subset is meaningfully smaller than that headline figure.
Obesity and metabolic disease represent the largest, longest-dated and highest-optionality opportunity: the global GLP-1 market is forecast at approximately $92 billion in 2026, with estimates ranging up to $150 billion-plus by the early 2030s. Given how early-stage ARO-INHBE and ARO-ALK7 remain, any TAM estimate here is necessarily speculative — a multi-year call option rather than a near-term revenue driver. Summing across the pipeline, near-term markets (FCS, HoFH) are individually modest while mid- and long-term opportunities (SHTG, HTG, MASH, obesity) are potentially transformative — meaning the current $10–12 billion market cap already prices in meaningful probability-weighted success across several expansion vectors.
The addressable market expands in layers: FCS validates the drug, SHTG can validate the franchise, and obesity could validate the platform.
The Obesity and Metabolic Option
Can RNAi become a durable companion to incretin therapy?
The obesity programmes test two propositions at once: can TRiM deliver effective RNAi activity in adipose-linked biology, and can a genetic medicine improve the composition and durability of weight loss produced by incretin drugs? ARO-INHBE silences hepatic INHBE, reducing Activin E, a ligand regulating adipose energy homeostasis; human genetic data show loss-of-function INHBE variants are associated with lower obesity and type 2 diabetes risk. ARO-ALK7 targets a parallel, mechanistically distinct adipose pathway (ACVR1C/ALK7), giving Arrowhead two independent genetic bets in metabolic disease.
The commercial logic is adjunctive, not competitive: patients would use an infrequently dosed RNAi medicine alongside tirzepatide or another incretin to deepen fat loss, preserve lean tissue and improve metabolic outcomes. Interim Phase 1/2a data showed a single 400mg ARO-INHBE dose achieving ~85% mean maximum Activin E reduction, a 15.6% placebo-adjusted visceral fat reduction at week 16 as monotherapy, and — combined with tirzepatide — roughly double the weight loss and triple the fat reduction versus tirzepatide alone. Data at EASL 2026 showed a 44% placebo-adjusted liver fat reduction at doses of 200mg or higher, opening a second, MASH-focused development path.
That positioning reduces direct competition with Eli Lilly and Novo Nordisk, but raises a high evidentiary bar: Arrowhead must show an incremental benefit large enough to justify an additional therapy. Early findings do not yet establish long-term safety, persistence, cardiovascular benefit, payer acceptance or scalable combination economics. The correct investment treatment is disciplined optionality — meaningful upside if replicated, limited base-case value until larger controlled studies confirm the signal.
The obesity franchise could become Arrowhead’s largest asset class, but it should not be used to rescue an otherwise weak valuation case. Investors should demand success in the lipid franchise first and let obesity create upside.
Partnerships, Catalysts and Financial Capacity
Do non-dilutive economics genuinely reduce risk, or merely postpone the funding test?
Arrowhead has repeatedly monetised programmes while retaining its highest-conviction cardiometabolic assets. Amgen controls olpasiran; Takeda advances fazirsiran; GSK holds important liver programmes; Sarepta adds CNS and pulmonary reach. These agreements validate Arrowhead’s target selection and generate milestones and royalties — but partner priorities can change, and out-licensed assets deliver only a fraction of their gross economics.
The near-term catalyst calendar is unusually concentrated around plozasiran’s SHASTA-3, SHASTA-4 and MUIR-3 outcomes and the regulatory path for broader triglyceride indications. Zodasiran, fazirsiran, and pulmonary/CNS readouts provide additional layers of value, while the obesity programmes remain the longest-duration optionality.
Arrowhead reported substantial liquidity after financing and partner receipts, but the relevant question is not simply cash on hand — it is whether cash, milestones and early commercial revenue can carry a broad late-stage portfolio through data, filing and launch without repeated dilution. Financial capacity should be judged against the whole programme calendar, not a static runway headline.
- Plozasiran label expansion (SHASTA-3/4, MUIR-3)
- REDEMPLO commercial uptake and reimbursement
- Zodasiran and fazirsiran late-stage progress
- Obesity franchise replication (ARO-INHBE / ARO-ALK7)
- Extrahepatic platform validation (lung, CNS)
Partnerships allow Arrowhead to run a pipeline larger than its standalone income statement would normally support.
What Could Break the Thesis
What would disprove the Arrowhead investment thesis?
Company-Specific
- Concentration risk: near-term case is disproportionately dependent on plozasiran’s FCS/SHTG/HTG success
- First-in-class commercial execution risk — REDEMPLO is Arrowhead’s first-ever independently commercialized product
- Multiple simultaneous Phase 3 trials compress clinical and operational risk into a short window
- Key-person dependency on a nearly two-decade CEO tenure
- Manufacturing concentration in the Madison, WI facility
Industry / Market
- Ionis’s Tryngolza already holds first-mover advantage in SHTG
- ANGPTL3 space crowding: Evkeeza, Verve/Lilly, Regeneron/Alnylam siRNA
- Obesity field moving fast; today’s differentiation may not persist through a multi-year Phase 3 timeline
- Regulatory and reimbursement bar rises materially for large-population indications
Financial
- REDEMPLO revenue not expected to be material to FY2026 — runway funds the Phase 3 slate
- $60K ultra-orphan pricing unlikely to survive SHTG/HTG label expansion intact
Macro
- Biotech financing conditions and interest-rate sensitivity
- US drug-pricing policy risk (IRA Medicare negotiation and related proposals)
Diversification should be measured by independent sources of value, not by programme count. Plozasiran remains the dominant near-term driver.
The Muffett Verdict
What must be true for Arrowhead to become one of the defining RNA medicine companies of the next decade?
Our conclusion is deliberately conditional. Arrowhead is scientifically credible, strategically ambitious and materially more mature than it was before 2025. The next phase is not about proving that RNAi works; it is about proving that Arrowhead can allocate capital, sequence programmes and scale commercial execution well enough to capture the economics of the science.
Bull Case
Compounding validation: REDEMPLO demonstrates that Arrowhead can create and commercialise a wholly owned RNAi medicine. Successful expansion into severe and broader hypertriglyceridaemia would turn that product into a franchise. Zodasiran, partnered programmes and extrahepatic delivery would diversify the earnings base. Replicated obesity data could then add a genuinely new growth engine.
Bear Case
Plozasiran expansion disappoints, the commercial organisation struggles beyond an ultra-orphan niche, obesity signals fail to reproduce, and the company continues to consume capital across too many simultaneous programmes. In that scenario, pipeline breadth becomes expense rather than advantage.
Arrowhead evolves from a first-product biotech into a diversified RNAi franchise: plozasiran establishes a broad cardiometabolic base, TRiM repeatedly opens new tissues, and obesity becomes upside rather than the foundation of the thesis.
Investment Checklist
- REDEMPLO prescriptions, reimbursement and geographic rollout
- SHASTA-3/4 and MUIR-3 efficacy, safety and regulatory interpretation
- Evidence that broader labels can support population-scale pricing
- Zodasiran and fazirsiran late-stage execution
- Replication of ARO-INHBE and ARO-ALK7 body-composition signals
- Clinical proof that pulmonary and CNS delivery are repeatable
- Cash consumption relative to the catalyst calendar
Selected Sources
Principal evidence used in this dossier includes Arrowhead filings and investor materials, clinical publications and trial records, regulatory announcements, and independent market research. Figures and claims should be refreshed before publication when new clinical or quarterly data are released.
- Arrowhead Pharmaceuticals DEF 14A Proxy Statement, filed January 26, 2026, SEC EDGAR (CIK 0000879407)
- Arrowhead Pharmaceuticals official pipeline page — arrowheadpharma.com/en-us/pipeline (accessed July 2026)
- Arrowhead Pharmaceuticals Q1/Q2 FY2026 earnings materials and 8-K filings, SEC EDGAR
- “Plozasiran (ARO-APOC3) for Severe Hypertriglyceridemia: The SHASTA-2 Randomized Clinical Trial” — JAMA Cardiology / PubMed
- “Rationale and design of the SHASTA-3 and SHASTA-4 studies” — European Heart Journal / Oxford Academic
- “Arrowhead Pharmaceuticals Presents New Clinical Data on RNAi-based Obesity and MASH Candidate ARO-INHBE at EASL 2026” — Arrowhead IR
- “Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-INHBE for the Treatment of Obesity” — Arrowhead IR
- “Arrowhead Pharmaceuticals Appoints Daniel Apel as Chief Financial Officer” — BioSpace / Arrowhead IR
- “Ionis’ TRYNGOLZA Enters the Severe Hypertriglyceridemia Space” — DelveInsight
- “Arrowhead Pharmaceuticals’ Zodasiran: A Pioneering ANGPTL3 Inhibitor for HoFH and Beyond” — AInvest
- “Evinacumab (Evkeeza) Market Forecast” — Grand View Research
- “Severe Hypertriglyceridemia Market Poised for Transformational Growth” — DelveInsight
- “How Supply and Demand for Weight Loss Drugs is Playing Out in 2026” — J.P. Morgan Research
- “The anti-obesity drug market may prove smaller than expected” — Goldman Sachs Research
- stockanalysis.com — Arrowhead Pharmaceuticals (ARWR) stock price and market cap, accessed July 2026
- “Arrowhead (ARWR) FQ1 2026 Revenue Hits $264M as REDEMPLO Approval Marks Commercial Shift” — Insider Monkey
Note: all figures reflect publicly available information as of July 2026 and are subject to change as the company reports subsequent quarterly results and clinical trial data. This publication is for informational purposes only and does not constitute investment advice.